This community is in archive. Visit community.xprize.org for the current XPRIZE Community.

Resources for the Longevity XPRIZE

AlexZhavoronkovAlexZhavoronkov Posts: 7 ✭✭
edited March 2019 in The Future of Longevity
Here I would like to propose and describe several useful resources for the longevity X-Prize developed by my team and in collaborations:

Online sandbox and playground for aging biomarkers (we can white box it for X-Prize):
www.young.ai

Curated databases of geroprotectors:
www.geroprotectors.org
Publication:
Geroprotectors.org: a new, structured and curated database of current therapeutic interventions in aging and age-related disease. Aging (Albany NY). 2015 Sep;7(9):616-28. PubMed PMID: 26342919; PubMed Central PMCID: PMC4600621.

http://genomics.senescence.info/drugs/
Publication:
The DrugAge database of aging-related drugs. Aging Cell. 2017 Jun;16(3):594-597. doi: 10.1111/acel.12585. Epub 2017 Mar 16. PubMed PMID: 28299908; PubMed Central PMCID: PMC5418190.

Wikipedia of aging pathways:
www.agingchart.org

Search engine for biomedical grants and publications:
www.agingportfolio.org

Publication:
Methods for structuring scientific knowledge from many areas related to aging research.
https://journals.plos.org/plosone/

One simple research paper describing the applications of AI to longevity (biomarkers and therapeutics):
Artificial Intelligence for Aging and Longevity Research: Recent Advances and Perspectives. Ageing Res Rev. 2018 Nov 22. pii: S1568-1637(18)30240-X. doi: 10.1016/j.arr.2018.11.003. PubMed PMID: 30472217.

Analytical Reports covering the longevity biotechnology industry:
www.AgingAnalytics.com

Comments

  • NickOttensNickOttens Posts: 899 admin
    Thank you for sharing! These should be useful to everyone here.
  • efoehrefoehr Posts: 8
    Are you aware of resources to identify clinically relevant endpoints for aging (besides waiting decades to measure overall mortality)? Any intervention to slow the aging process (i.e. medical device or pharmaceutical) would need to have some endpoint that the FDA would accept. For instance grip strength, cognition, muscle mass, or cardiac output could be useful. Circulating biomarkers may also be informative --but which ones?
  • AlexZhavoronkovAlexZhavoronkov Posts: 7 ✭✭
    @efoehr, I listed some of these resources above. One of these resources is young.ai
  • ymedanymedan Posts: 127 ✭✭✭
    See what the EU has been doing
    https://ec.europa.eu/eip/ageing/home_en

    They do use 2 major metrics that I have seen:
    1. Healthy life expectancy
    2. Disablity free life expectancy

    With current morbidities, #1 is getting smaller so there is no need to wait for EOLife.
Sign In or Register to comment.